Pharmacological Reports Copyright © 2005 2005, 57, 545–549 by Institute of Pharmacology ISSN 1734-1140 Polish Academy of Sciences

Short communication

Antinociception after intrathecal biphalin application in rats: a reevaluation and novel, rapid method to confirm correct catheter tip position

Dariusz Kosson1,2, Iwona Bonney1,3, Daniel B. Carr3, Ewa Mayzner-Zawadzka2, Andrzej W. Lipkowski1,3

Medical Research Centre, Polish Academy of Sciences, Pawiñskiego 5, PL 02-106Warszawa, Poland

Department of Anesthesiology, Medical School, Lindley 4, PL 02-005 Warszawa, Poland

!Department of Anesthesia, Tufts-New England Medical Center, 750 Washington, Boston, MA 02111, USA

Correspondence: Andrzej W. Lipkowski, e-mail: [email protected]

Abstract: The dimmer biphalin [(Tyr-D-Ala-Gly-Phe-NH-) ] has high potency both in vivo and in vitro. Its antinociceptive activity depends on the route of administration: the lowest potency is after subcutaneous, and the highest after intrathecal or inracerebroventricular administration. We tested the activity of biphalin in a wide range of doses after intrathecal administration to rats. Doses as low as 0.005 nmol produced significant analgesia. Increasing the dose up to 2 nmol elevated and prolonged antinociception without any evident side effects, indicating that biphalin is an extremely potent opioid after intrathecal application with a wide therapeutic window. The highest dose tested (20 nmol) produced full analgesia and body rigidity lasting 2–3 h. After muscle tone returned to normal, antinociception lasted for several more hours. During these studies we observed a correlation between responses to biphalin and catheter placement. Postmortem verification of catheter placement revealed that in those rats in which high-dose biphalin did not produce analgesia or muscle rigidity, the catheter was positioned incorrectly or the flow of drug solution was obstructed. Therefore, a secondary conclusion is that assessment of transient rigidity after administration of a high dose of biphalin may be used as an easy method to confirm intrathecal placement of the catheter.

Key words: biphalin, , antinociception, pain, intrathecal

Introduction goal of traditional drug development, including pep- tide structures is to generate systematically active agents that may be given orally or at least intrave- The discovery of opioid thirty years ago nously. This mainstream approach to drug develop- opened a new chapter in the study of pain pathogene- ment has tremendously lessened interest in peptides sis and modulation [4] This discovery also created as potential drugs. Several years ago we proposed to hopes for new types of . However, a major change our way of thinking about peptides as poten-

Pharmacological Reports, 2005, 57, 545–549 545 tial drugs. Modern alternative modes of drug delivery Intrathecal catheterization allow for the design of a new generation of drugs whose biological properties mimic those of the en- For spinal drug administration, rats were implanted it dogenous peptides, such as low permeability across with chronic indwelling catheters according to biological barriers and limited resistance to peptidases a modification [1] of the method described by Yaksh [8]. Biphalin is one example of an ana- and Rudy [13]. Briefly, through an incision in the atlanto-occipital membrane, silastic tubing was in- logue that is under development as an analgesic agent. serted to a distance of 7.5 cm, thereby positioning the Biphalin infusion for 5 days intravenously at an tip at the T13-L1 spinal level. To facilitate threading antinociceptive dosage equipotent to morphine is not the catheter through the intrathecal space, a stylet was followed by significant withdrawal signs in rats upon inserted into the silastic tubing. After catheter place- challenge [14]. However, biphalin possesses ment, the stylet was removed and the catheter was se- uniquely high potency both in vitro and in vivo [10]. cured by sutures. After surgery, animals were housed Chemically, biphalin is comprised of two individually. Rats were given 2 days to recover from analog pharmacophores connected “head-to-head” surgery, during which time they were habituated daily through a hydrazide bridge [2, 6]. It has high, nearly to the laboratory environment and analgesic testing m d equal affinity for both and and moderate affinity apparatus. Each experimental group consisted of k for opioid receptors [7, 12]. Biphalin administered 6 rats. Each rat was tested only once. All intrathecal sc subcutaneously ( ) to rats displays lower analgesic injections were made in the same volume (10 ml fol- potency than morphine in the tail flick test. When in- lowed by 10 ml of saline for flushing the dead space of iv jected intravenously ( ), its potency increases mark- the catheter). All drugs were dissolved in sterile 0.9% edly but its analgesic activity is of a shorter duration saline solution. Biphalin hydrochloride (M.W. 1000) and its potency is still less than that of morphine [11]. was administered at doses of 0.001, 0.005, 0.0125, Administered intracerebroventricularly (icv), biphalin 0.025, 0.5, 2 and 20 nmol. Morphine hydrochloride has been shown to be 3-fold more potent than mor- (M.W. 322) 7.8 nmol was administered intrathecally phine and almost 7-fold more potent than in to rats according to the same experimental protocol as eliciting antinociception [3]. Biphalin administered it an active control for biphalin antinociceptive effects. to rats produces intense and long-lasting analgesia [9, 11]. Nevertheless, we have observed in our laboratory Tail flick test [5], as have others that the variability of the analgesic response to peptides, including biphalin, applied di- For measurement of thermal antinociception, a tail rectly to the central nervous system (it,oriv)issig- flick apparatus was utilized. Light intensity was ad- nificantly greater than that of . The experi- justed to yield a mean baseline latency of approxi- ments described herein were initiated in order to char- mately 3.5 s with automatic cutoff at7stoavoid tail acterize this analgesic variability by reevaluating the damage. Analgesic measurements were performed be- antinociceptive effects of a wide range of biphalin fore drug administration and 5, 15, 30, 60 and doses in rats after it administration. 120 min after drug or 0.9% saline solution (control group) administration. Antinociceptive responses were expressed as % maximum possible effect (%MPE) and calculated according to the following formula: Materials and Methods posttreatment latency– baseline latency %MPE = x100 cutoff time– baseline latency All experimental procedures were approved by Local Animal Research Committee. Adult male Sprague- Dawley rats (225–250 g) were housed in groups of Data were expressed as the mean %MPE ± standard 3 per cage and maintained on a 12 h light/12 h dark deviation for each measurement time. Differences cycle. Animals had free access to food and water at all between groups were analyzed using one-way times. ANOVA for comparison at each time point. The t-test

546 Pharmacological Reports, 2005, 57, 545–549 Intrathecal antinociception of biphalin Dariusz Kosson et al.

100

80

60

40

MPE

% 20

0 5 15 30 60 120 –20 time (min) Saline Biphalin 0.001 nmol 0.005 nmol 0.0125 nmol 0.5 nmol 2.0 nmol

Fig. 1. Antinociceptive effects of biphalin (0.005–2 nmol) administered intrathecally to rats, as measured by tail flick testing. Dosage increases produced more intense and prolonged analgesia

was used to compare %MPE between treatment analgesia (15 min) with 60–70% MPE peak antino- groups. P < 0.05 was considered statistically signifi- ciception (Fig. 1). The same it dose of biphalin cant. (0.005 nmol) produced a more rapid onset of analge- sia than morphine (7.8 nmol) (Fig. 2). Biphalin dos- Catheter position verification age increases produced more intense and prolonged analgesia (Fig. 1). After completion of drug testing, a standard method Intrathecal injection of 20 nmol of biphalin to rats of catheter position verification was employed: ex- caused long-lasting analgesia and body rigidity. This amination of the spinal cord postmortem after pre- rigidity persisted for 2 h without any other apparent sacrifice injection of indigo blue. Because this opioid-related adverse effects, e.g. the lethal respira- method is very time-consuming, catheter placement tory depression observed after high doses of mor- was verified only in selected animals. In those ani- phine. After 2–3 h the rats’ muscle tone returned to mals we observed that the location of catheter corre- lated well with the occurrence of rigidity after high dose it biphalin administration. Therefore, the effect of post-experimental injection of 20 nmol of biphalin 100 it was explored as a method to verify proper catheter 80 location and function. The prior experimental data of 60 animals that did not display such side effects in re- sponse to bolus it injection of biphalin were retrospec- 40 tively dropped from the experimental analyses. 20 0 5 153060120 time Biphalin 0.005 nmol Morphine 7.8 nmol Results

Fig. 2. Antinociceptive time profile of nearly equipotent doses of Biphalin at the lowest dose tested (0.001 nmol) did biphalin (0.005 nmol) and morphine (7.8 nmol) administered it intrathecally to rats, as measured by tail flick testing. There is not produce any effects. Biphalin administered at a significantly greater (* p < 0.05) antinociceptive effect of morphine the increased dose (0.005 nmol) produced transient than biphalin at 120 min after injection

Pharmacological Reports, 2005, 57, 545–549 547 normal, but antinociception persisted for several fur- biphalin molecule as compared with the smaller and ther hours. After two days the animals’ behavior, in- more lipophilic . Discarding the results ob- cluding tail flick latency to a thermal stimulus, re- tained from antinociceptive testing in rats with mis- turned to normal. The postmortem examination placed or malfunctioning catheters resulted in signifi- showed that in all animals that did not exhibit rigidity cantly augmented analgesic effects. Hence, the occur- in response to 20 nmol biphalin, the placement of the rence of temporary rigidity after challenge with a high catheter was incorrect or it was kinked, and as a con- dose of it biphalin may be used as an easy test to con- sequence, the tested compound did not reach the in- firm proper placement of lumbar intrathecal catheters. trathecal space. Thus, the post-experimental, pre-sacrifice intrathecal application of 20 nmol of biphalin, followed by screening for skeletal muscle rigidity, is an efficient and humane means to confirm lumbar intrathecal Discussion catheter tip placement. Although observation of mo- tor block after instillation of local anesthetic such as lidocaine is another approach to confirm it catheter tip Biphalin injected intrathecally produced a dose- position, large and/or concentrated doses may be re- dependent antinociceptive effect in acute thermal test- quired. Such doses may prove lethal and also, because ing in rats. Doses as low as 0.005 nmol produced sig- epidural lidocaine may also produce sensorimotor nificant analgesia. Increasing the dose up to 2 nmol block, may lack specificity. In contrast, the absence of proportionally elevated and prolonged antinocicep- lethal side effects after intrathecal biphalin admini- tion without any evident side effects. These findings stration up to 20 nmol, indicates that biphalin is a safe confirm observations by us and others that it biphalin and effective drug for intrathecal analgesia. produces intense analgesia with a wide therapeutic window. We incidentally noted that not all of the rats responded to biphalin in a similar manner. In about ten percent of animals tested, biphalin did not produce References: any apparent effect. Postmortem verification of cathe- ter location revealed malpositioning and/or malfunction of the catheter in those rats. Administration of 20 nmol 1. Foran SE, Carr DB, Lipkowski AW, Maszczynska I, of biphalin to rats with proper catheter placement con- Marchand JE, Misicka A, Beinborn M et al.: Inhibition of morphine tolerance development by a - sistently produced transient muscle rigidity. This opioid peptide chimera. J Pharmacol Exp Ther, 2000, rigidity was not accompanied by respiratory depres- 295, 1142–1148. sion (the lethal side effect occurring after overdose of 2. Hettiarachchi K, Ridge S, Thomas DW, Olson L, Obi morphine). The muscle rigidity lasted up to 3 h, after CR, Singh D: Characterization and analysis of biphalin: which animals’ locomotor activity returned to normal. an opioid peptide with a palindromic sequence. J Peptide However, antinociceptive effects in those rats lingered Res, 2001, 57, 151–161. 3. Horan PJ, Mattia A, Bilsky EJ, Weber SJ, Davis TP, Ya- for several more hours. Subsequently, we employed mamura HI, Malatynska E et al.: Antinociceptive profile challenges with it injection of a high (20 nmol) dose of biphalin, a dimeric enkephalin analog. J Pharmacol of biphalin as a simple, minimally invasive means to Exp Ther, 1993, 265, 1446–1454. verify proper it catheter placement. Rats with clogged 4. Lipkowski AW, Carr DB: Rethinking opioid equivalence. or malpositioned catheters displayed no muscle rigid- Pain. Clinical Updates, 2002, 10, 1–4. 5. ity after this high dose of biphalin. Therefore, we be- Lipkowski AW, Carr DB, Silbert BS, Cepeda MS, Szy- it felbein SK: Non-deterministic individual responses to lieve that temporal rigidity after 20 nmol of biphalin receptor-selective opioid agonists. Pol J Pharmacol, 1994, may be used as an indicator of proper catheter loca- 46, 29–35. tion in the lumbar intrathecal space. We also noticed 6. Lipkowski AW, Konecka AM, Sroczynska I: Double- (without systematic study) that catheter malposition – synthesis, activity on guinea pig ileum and did not impair morphine antinociception to the same analgesic effect. Peptides, 1982, 3, 697–700. 7. Lipkowski AW, Konecka AM, Sroczynska I, Przewlocki degree as biphalin. This seeming discrepancy in R, Stala L, Tam SW: Bivalent opioid analogues with re- antinociceptive effects is probably the result of lower duced distances between pharmacophores. Life Sci, dural permeability of the larger, more hydrophilic 1987, 40, 2283–2288.

548 Pharmacological Reports, 2005, 57, 545–549 Intrathecal antinociception of biphalin Dariusz Kosson et al.

8. Lipkowski AW, Misicka A, Hruby VJ, Carr DB: Opioid routes of administration. Agents Actions, 1991, 33, peptide analogues: Reconsideration as a potentially new 382–387. generation of analgesics. Pol J Chem, 1994, 68, 907–912. 12. Slaninova J, Appleyard SM, Misicka A, Lipkowski AW, # 9. Misterek K, Maszczynska I, Dorociak A, Gumulka SW, Knapp RJ, Weber SJ, Davis TP et al.: [ I-Tyr ]biphalin Carr DB, Szyfelbein SK, Lipkowski AW: Spinal co-ad- binding to opioid receptors of rat brain and NG108-15 miministration of peptide substance P antagonist increases cell membranes. Life Sci, 1998, 62, PL199–204. antinociceptive effect of the opioid peptide biphalin. Life 13. Yaksh TL, Rudy TA: Chronic catheterization of the spi- Sci, 1994, 54, 939–944. nal cord subarachnoid space. Physiol Behav, 1976, 17, 10. Shen K-F, Crain SM: Biphalin, an enkephalin analog with 1031–1033. 14. unexpectedly high antinociceptive potency and low de- Yamazaki M, Suzuki S, Narita M, Lipkowski AW: The pendence liability in vivo, selectively antagonizes excita- opioid peptide analogue biphalin induces less physical tory functions of sensory neurons in cul- dependence than morphine. Life Sci, 2001, 69, 1023–1028. ture. Brain Res, 1995, 701, 158–166. 11. Silbert BS, Lipkowski AW, Cepeda MS, Szyfelbein SK, Osgood PF, Carr DB: Analgesic activity of a novel biva- Received: lent opioid peptide compared to morphine via different February 15, 2005; in revised form: May 31, 2005.

Pharmacological Reports, 2005, 57, 545–549 549